N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
A method for treating and/or preventing polycystic ovary syndrome (PCOS) including the administration, to a patient in need thereof, of a pharmaceutically effective amount of a compound of Formula I or a pharmaceutically acceptable solvate thereof.
1. A method for preventing and/or treating moderate hot flashes or severe hot flashes in a patient, wherein the method comprises administering to the patient in need thereof for at least four weeks a pharmaceutically effective amount of the following compound:
wherein the frequency of moderate hot flashes or severe hot flashes in the patient after at least four weeks of treatment is reduced compared to the frequency of moderate hot flashes or severe hot flashes in the patient before at least four weeks of treatment.
2. The method according to claim 1 , wherein the moderate hot flashes or severe hot flashes are related to a condition selected from the group consisting of a perimenopausal condition, a menopausal condition, and a postmenopausal condition, or a combination thereof.
3. The method according to claim 1 , wherein the moderate hot flashes or severe hot flashes are a consequence of hormone therapy which intentionally lowers the level of sex hormones.
4. The method according to claim 3 , wherein the moderate hot flashes or severe hot flashes are selected from the group consisting of therapy-induced moderate hot flashes in breast cancer, therapy-induced severe hot flashes in breast cancer, therapy-induced moderate hot flashes in uterine cancer, therapy-induced severe hot flashes in uterine cancer, therapy-induced moderate hot flashes in prostate cancer, and therapy-induced sever hot flashes in prostate cancer.
5. A method for preventing and/or treating moderate hot flashes or severe hot flashes in a patient, wherein the method comprises administering to the patient in need thereof for at least four weeks a pharmaceutically effective amount of the following compound:
wherein the severity of moderate hot flashes or severe hot flashes in the patient after at least four weeks of treatment is reduced compared to the severity of moderate hot flashes or severe hot flashes in the patient before at least four weeks of treatment.
6. The method according to claim 5 , wherein the moderate hot flashes or severe hot flashes are related to a condition selected from the group consisting of a perimenopausal condition, a menopausal condition, and a postmenopausal condition, or a combination thereof.
7. The method according to claim 5 , wherein the moderate hot flashes or severe hot flashes are a consequence of hormone therapy which intentionally lowers the level of sex hormones.
8. The method according to claim 7 , wherein the moderate hot flashes or severe hot flashes are selected from the group consisting of therapy-induced moderate hot flashes in breast cancer, therapy-induced severe hot flashes in breast cancer, therapy-induced moderate hot flashes in uterine cancer, therapy-induced severe hot flashes in uterine cancer, therapy-induced moderate hot flashes in prostate cancer, and therapy-induced sever hot flashes in prostate cancer.